<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347762</url>
  </required_header>
  <id_info>
    <org_study_id>2010-P-000096</org_study_id>
    <secondary_id>1K99DA029115-01</secondary_id>
    <nct_id>NCT01347762</nct_id>
  </id_info>
  <brief_title>Nabilone for Cannabis Dependence: A Pilot Study</brief_title>
  <acronym>NAB CAN</acronym>
  <official_title>Nabilone for Cannabis Dependence: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cannabis use disorders are an important public health problem in the United States, but there
      are no effective medications available to treat these disorders. The investigators intend to
      test a medication with interesting properties, nabilone, as a treatment for cannabis
      dependence and to study the relationship of this treatment with the brain using functional
      MRI brain scans. Nabilone and marijuana have similar effects upon behaviors and the human
      body, suggesting that nabilone may decrease cannabis withdrawal symptoms while allowing
      treatment-seeking patients to benefit from behavioral treatments when they are trying to stop
      using cannabis. The investigators propose to assess the relationship of nabilone, when added
      to behavioral treatment, on cannabis use patterns in cannabis-dependent patients. The
      investigators also aim to determine the effects of nabilone on performance on
      neuropsychological tests and to assess the correlation of neuropsychological performance to
      brain changes using functional MRI brain scans. The investigators hypothesize that patients
      receiving nabilone will reduce their use of cannabis more than patients receiving placebo
      during this 10-week treatment trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cannabis use disorders are an important public health problem in the United States, but no
      effective pharmacotherapies are available to treat these disorders. The investigators intend
      to test a novel agonist pharmacotherapy, nabilone, for cannabis dependence and to study the
      relationship of this treatment with the brain using BOLD fMRI measures. The behavioral and
      physiological effects of nabilone and Î”9-THC overlap, suggesting that nabilone may ameliorate
      cannabis withdrawal symptoms while allowing treatment-seeking outpatients to benefit from
      medical management (MM) sessions when they are trying to stop using cannabis. The
      investigators propose to assess the relationship of nabilone, when added to MM, on cannabis
      use patterns in cannabis-dependent patients. The investigators also aim to determine the
      effects of nabilone on performance on neuropsychological tests and to assess the correlation
      of neuropsychological performance to brain changes using BOLD fMRI measures.

      In this pilot study, subjects will receive either nabilone or placebo in addition to medical
      management (MM) over a 10-week treatment period. Subjects' responses to neuropsychological
      testing carried out while the subject is receiving fMRI scans at 3 time points: at baseline,
      4 weeks, and 10 weeks. Following treatment completion, subjects will have a follow-up visit
      at 14 weeks. This pilot study will evaluate the feasibility of nabilone treatment for
      cannabis dependence and will establish effect sizes for a larger trial in which subjects will
      receive high-dose nabilone, low-dose nabilone, or placebo in addition to MM.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 9, 2017</completion_date>
  <primary_completion_date type="Actual">June 9, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Cannabis Use at 10 Weeks</measure>
    <time_frame>baseline and 10 weeks</time_frame>
    <description>Quantitative cannabis urine screens (THC-COOH:Creatinine ratio)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Marijuana Inhales Per Day</measure>
    <time_frame>Week 10</time_frame>
    <description>Average # of marijuana inhales per day during baseline compared to after 10 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Neuropsychological Performance at 4 Weeks</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>performance on neuropsychological tests administered inside of the fMRI scanner and outside of the fMRI scanner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Cannabis Use at 14 Weeks</measure>
    <time_frame>baseline and 14 weeks</time_frame>
    <description>quantitative urine screens - Comparing the THC-COOH to creatinine ratio at baseline and at the end of the study (Week 14)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neuropsychological Performance at 10 Weeks</measure>
    <time_frame>baseline and 10 weeks</time_frame>
    <description>performance on neuropsychological tests administered inside of the fMRI scanner and outside of the fMRI scanner</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Cannabis Dependence</condition>
  <condition>Marijuana Dependence</condition>
  <arm_group>
    <arm_group_label>Nabilone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nabilone titrated to 2 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nabilone</intervention_name>
    <description>nabilone titrated to 1 mg by mouth twice daily</description>
    <arm_group_label>Nabilone</arm_group_label>
    <other_name>Nabilone (Cesamet), CSA Drug Code 7379, Schedule II, NDC 0037-1221-50</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one placebo capsule by mouth twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range 18-45 years

          -  DSM-IV diagnosis of cannabis dependence, based on the Structured Clinical Interview
             for DSM-IV (SCID)

          -  express a desire to quit cannabis use within the next 30 days

          -  have used cannabis on more than4 days within the past 30 days

          -  for women of childbearing age, a negative pregnancy test at screening with agreement
             to use adequate contraception to prevent pregnancy and monthly pregnancy tests

          -  consent for us to communicate with their prescribing clinician

          -  furnish the names of 2 locators, who would assist study staff in locating them during
             the study period

          -  live close enough to McLean Hospital to attend study visits

          -  plan to stay in the Boston area for the next 3 months

          -  are willing and able to sign informed consent.

        Exclusion Criteria:

          -  current diagnosis of other drug or alcohol dependence (excluding nicotine)

          -  recent (within 3 months) significant cardiac disease

          -  current serious psychiatric illness or history of psychosis, schizophrenia, bipolar
             type I disorder

          -  current medical condition (including significant laboratory abnormalities, such as
             liver function tests &gt;5 times the upper limit of normal range) that could prevent
             regular study attendance

          -  mental retardation or organic mental disorder

          -  acutely dangerous or suicidal behavior

          -  currently in a residential treatment setting in which substance use is monitored and
             restricted, since the restricted access to drugs could represent an important
             confounding variable

          -  pregnant, nursing, or, if a woman of childbearing potential, not using a form of birth
             control judged by the investigator to be effective

          -  concomitant daily treatment with opioid analgesics, sedative hypnotics, or other known
             CNS depressants

          -  known hypersensitivity to cannabinoids or sesame oil

          -  disease of the gastrointestinal system, liver, or kidneys that may impede metabolism
             or excretion of nabilone

          -  inability to read or write in English. The potential hazards of a Schedule II
             medication like nabilone underscore the importance of English proficiency in this
             medication trial.

          -  unwilling or unable to participate in MRI scanning (e.g., those having pacemakers,
             bone plates, screws, etc.; claustrophobia)

          -  a history of seizures, head trauma or other history of CNS insult that could
             predispose the subject to seizures .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin P Hill, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>April 26, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <results_first_submitted>May 30, 2018</results_first_submitted>
  <results_first_submitted_qc>May 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 1, 2018</results_first_posted>
  <last_update_submitted>May 30, 2018</last_update_submitted>
  <last_update_submitted_qc>May 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Kevin P. Hill, MD, MHS</investigator_full_name>
    <investigator_title>Psychiatrist-In-Charge</investigator_title>
  </responsible_party>
  <keyword>cannabis dependence</keyword>
  <keyword>marijuana dependence</keyword>
  <keyword>cannabis use disorders</keyword>
  <keyword>cannabis withdrawal</keyword>
  <keyword>nabilone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nabilone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT01347762/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>14 potential subjects were screened but did not qualify for Phase 1 and 18 for Phase 2. Reasons included: positive urine screen for opiates or cocaine, lost to follow up after screening visit, withdrew from the study due to time constraints before randomization, met criteria for alcohol dependence or did not test positive for THC urine screen</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nabilone Titrated 2 mg Daily (Phase 1)</title>
          <description>nabilone titrated to 2 mg daily
Nabilone: nabilone titrated to 1 mg by mouth twice daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Phase 1)</title>
          <description>Placebo
Placebo: one placebo capsule by mouth twice daily</description>
        </group>
        <group group_id="P3">
          <title>Nabilone Titrated to 4 mg Daily (Phase 2)</title>
          <description>nabilone titrated to 4 mg daily
Nabilone: nabilone titrated to 2 mg by mouth twice daily</description>
        </group>
        <group group_id="P4">
          <title>Placebo (Phase 2)</title>
          <description>Placebo
Placebo: one placebo capsule by mouth twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nabilone Titrated 2 mg Daily (Phase 1)</title>
          <description>nabilone titrated to 2 mg daily
Nabilone: nabilone titrated to 1 mg by mouth twice daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Phase 1)</title>
          <description>Placebo
Placebo: one placebo capsule by mouth twice daily</description>
        </group>
        <group group_id="B3">
          <title>Nabilone Titrated to 4 mg Daily (Phase 2)</title>
          <description>nabilone titrated to 4 mg daily
Nabilone: nabilone titrated to 2 mg by mouth twice daily</description>
        </group>
        <group group_id="B4">
          <title>Placebo (Phase 2)</title>
          <description>Placebo
Placebo: one placebo capsule by mouth twice daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="18"/>
            <count group_id="B5" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.40" spread="5.17"/>
                    <measurement group_id="B2" value="28.88" spread="7.53"/>
                    <measurement group_id="B3" value="27.81" spread="6.81"/>
                    <measurement group_id="B4" value="28.11" spread="7.26"/>
                    <measurement group_id="B5" value="27.42" spread="6.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Urine THC/Creatinine Ratio</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="491.6" spread="283.0"/>
                    <measurement group_id="B2" value="458.7" spread="568.9"/>
                    <measurement group_id="B3" value="633.2" spread="728.5"/>
                    <measurement group_id="B4" value="371.0" spread="265.4"/>
                    <measurement group_id="B5" value="489.8" spread="496.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average Number of Inhales of Marijuana Per Day</title>
          <units>Inhales per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.1" spread="43.8"/>
                    <measurement group_id="B2" value="27.1" spread="13.2"/>
                    <measurement group_id="B3" value="28.9" spread="31.8"/>
                    <measurement group_id="B4" value="16.53" spread="29.13"/>
                    <measurement group_id="B5" value="30.52" spread="33.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Cannabis Use at 10 Weeks</title>
        <description>Quantitative cannabis urine screens (THC-COOH:Creatinine ratio)</description>
        <time_frame>baseline and 10 weeks</time_frame>
        <population>Fewer participants had their THC:creatinine ratios analyzed than were randomized due to a high number of subject drop-out. Any subject who dropped out before completing the 10 weeks of treatment were not analyzed using this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Nabilone Titrated 2 mg Daily (Phase 1)</title>
            <description>nabilone titrated to 2 mg daily
Nabilone: nabilone titrated to 1 mg by mouth twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Phase 1)</title>
            <description>Placebo
Placebo: one placebo capsule by mouth twice daily</description>
          </group>
          <group group_id="O3">
            <title>Nabilone Titrated to 4 mg Daily (Phase 2)</title>
            <description>nabilone titrated to 4 mg daily
Nabilone: nabilone titrated to 2 mg by mouth twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Phase 2)</title>
            <description>Placebo
Placebo: one placebo capsule by mouth twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cannabis Use at 10 Weeks</title>
          <description>Quantitative cannabis urine screens (THC-COOH:Creatinine ratio)</description>
          <population>Fewer participants had their THC:creatinine ratios analyzed than were randomized due to a high number of subject drop-out. Any subject who dropped out before completing the 10 weeks of treatment were not analyzed using this measure.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268.8" spread="183.0"/>
                    <measurement group_id="O2" value="286.7" spread="349.7"/>
                    <measurement group_id="O3" value="490.3" spread="615.0"/>
                    <measurement group_id="O4" value="216.9" spread="188.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Marijuana Inhales Per Day</title>
        <description>Average # of marijuana inhales per day during baseline compared to after 10 weeks of treatment.</description>
        <time_frame>Week 10</time_frame>
        <population>Fewer participants had their &quot;average number of inhales per day&quot; analyzed than were randomized due to a high number of subject drop-out. Any subject who dropped out before completing the 10 weeks of treatment were not analyzed using this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Nabilone Titrated 2 mg Daily (Phase 1)</title>
            <description>nabilone titrated to 2 mg daily
Nabilone: nabilone titrated to 1 mg by mouth twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Phase 1)</title>
            <description>Placebo
Placebo: one placebo capsule by mouth twice daily</description>
          </group>
          <group group_id="O3">
            <title>Nabilone Titrated to 4 mg Daily (Phase 2)</title>
            <description>nabilone titrated to 4 mg daily
Nabilone: nabilone titrated to 2 mg by mouth twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Phase 2)</title>
            <description>Placebo
Placebo: one placebo capsule by mouth twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Marijuana Inhales Per Day</title>
          <description>Average # of marijuana inhales per day during baseline compared to after 10 weeks of treatment.</description>
          <population>Fewer participants had their &quot;average number of inhales per day&quot; analyzed than were randomized due to a high number of subject drop-out. Any subject who dropped out before completing the 10 weeks of treatment were not analyzed using this measure.</population>
          <units>Inhales per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8" spread="31.0"/>
                    <measurement group_id="O2" value="22.6" spread="30.6"/>
                    <measurement group_id="O3" value="15.8" spread="35.6"/>
                    <measurement group_id="O4" value="10.6" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Neuropsychological Performance at 4 Weeks</title>
        <description>performance on neuropsychological tests administered inside of the fMRI scanner and outside of the fMRI scanner</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <population>Due to funding and the principal investigator's change in institutions, this data was not analyzed and is no longer available to the investigator.</population>
        <group_list>
          <group group_id="O1">
            <title>Nabilone Titrated 2 mg Daily (Phase 1)</title>
            <description>nabilone titrated to 2 mg daily
Nabilone: nabilone titrated to 1 mg by mouth twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Phase 1)</title>
            <description>Placebo
Placebo: one placebo capsule by mouth twice daily</description>
          </group>
          <group group_id="O3">
            <title>Nabilone Titrated to 4 mg Daily (Phase 2)</title>
            <description>nabilone titrated to 4 mg daily
Nabilone: nabilone titrated to 2 mg by mouth twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Phase 2)</title>
            <description>Placebo
Placebo: one placebo capsule by mouth twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Neuropsychological Performance at 4 Weeks</title>
          <description>performance on neuropsychological tests administered inside of the fMRI scanner and outside of the fMRI scanner</description>
          <population>Due to funding and the principal investigator's change in institutions, this data was not analyzed and is no longer available to the investigator.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Cannabis Use at 14 Weeks</title>
        <description>quantitative urine screens - Comparing the THC-COOH to creatinine ratio at baseline and at the end of the study (Week 14)</description>
        <time_frame>baseline and 14 weeks</time_frame>
        <population>Fewer participants had their THC:creatinine ratios analyzed than were randomized due to a high number of subject drop-out. Any subject who dropped out before completing the 10 weeks of treatment were not analyzed using this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Nabilone Titrated 2 mg Daily (Phase 1)</title>
            <description>nabilone titrated to 2 mg daily
Nabilone: nabilone titrated to 1 mg by mouth twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Phase 1)</title>
            <description>Placebo
Placebo: one placebo capsule by mouth twice daily</description>
          </group>
          <group group_id="O3">
            <title>Nabilone Titrated to 4 mg Daily (Phase 2)</title>
            <description>nabilone titrated to 4 mg daily
Nabilone: nabilone titrated to 2 mg by mouth twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Phase 2)</title>
            <description>Placebo
Placebo: one placebo capsule by mouth twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Cannabis Use at 14 Weeks</title>
          <description>quantitative urine screens - Comparing the THC-COOH to creatinine ratio at baseline and at the end of the study (Week 14)</description>
          <population>Fewer participants had their THC:creatinine ratios analyzed than were randomized due to a high number of subject drop-out. Any subject who dropped out before completing the 10 weeks of treatment were not analyzed using this measure.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="524.2" spread="466.2"/>
                    <measurement group_id="O2" value="326.7" spread="403.7"/>
                    <measurement group_id="O3" value="297.7" spread="291.8"/>
                    <measurement group_id="O4" value="222" spread="186.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Neuropsychological Performance at 10 Weeks</title>
        <description>performance on neuropsychological tests administered inside of the fMRI scanner and outside of the fMRI scanner</description>
        <time_frame>baseline and 10 weeks</time_frame>
        <population>Due to funding and the principal investigator's change in institutions, this data was not analyzed and is no longer available to the investigator.</population>
        <group_list>
          <group group_id="O1">
            <title>Nabilone Titrated 2 mg Daily (Phase 1)</title>
            <description>nabilone titrated to 2 mg daily
Nabilone: nabilone titrated to 1 mg by mouth twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Phase 1)</title>
            <description>Placebo
Placebo: one placebo capsule by mouth twice daily</description>
          </group>
          <group group_id="O3">
            <title>Nabilone Titrated to 4 mg Daily (Phase 2)</title>
            <description>nabilone titrated to 4 mg daily
Nabilone: nabilone titrated to 2 mg by mouth twice daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Phase 2)</title>
            <description>Placebo
Placebo: one placebo capsule by mouth twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neuropsychological Performance at 10 Weeks</title>
          <description>performance on neuropsychological tests administered inside of the fMRI scanner and outside of the fMRI scanner</description>
          <population>Due to funding and the principal investigator's change in institutions, this data was not analyzed and is no longer available to the investigator.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from the time the subject was randomized up until the subject's last visit, this encompasses a total of 14 weeks per subject.</time_frame>
      <desc>During every visit (twice a week) a study staff member would ask the subject if they were experiencing any adverse events from the medication or participation in the study. Furthermore, during the weekly medication management session with the study physician, the physician asked and checked for adverse events as well</desc>
      <group_list>
        <group group_id="E1">
          <title>Nabilone Titrated 2 mg Daily (Phase 1)</title>
          <description>nabilone titrated to 2 mg daily
Nabilone: nabilone titrated to 1 mg by mouth twice daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Phase 1)</title>
          <description>Placebo
Placebo: one placebo capsule by mouth twice daily</description>
        </group>
        <group group_id="E3">
          <title>Nabilone Titrated to 4 mg Daily (Phase 2)</title>
          <description>nabilone titrated to 4 mg daily
Nabilone: nabilone titrated to 2 mg by mouth twice daily</description>
        </group>
        <group group_id="E4">
          <title>Placebo (Phase 2)</title>
          <description>Placebo
Placebo: one placebo capsule by mouth twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kevin P. Hill, M.D., M.H.S., Principal Investigator</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617 667 1597</phone>
      <email>khill1@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

